Adding the CDK4/6 inhibitor abemaciclib to endocrine therapy significantly improves overall survival in node-positive, ...

Overall survival outcomes in MATTERHORN trial support perioperative durvalumab plus chemotherapy as standard of care.

Although widely prescribed off-label to treat many types of chronic pain, experts warn of harmful side effects.

The EMA has recommended a first-in-class Bruton’s tyrosine kinase inhibitor to treat immune thrombocytopenia in adults who ...

Saphnelo can now be administered subcutaneously rather than intravenously following the European regulator’s recommendation.

Weekly intramuscular injections of rotigotine extended-release microspheres are linked to significant symptom improvement in ...

A large study suggests taking progesterone before pregnancy — not just after conception — may help reduce the risk for ...

The European Medicines Agency (EMA) has recommended granting marketing authorization in the EU for brensocatib (Brinsupri, ...

Patients with presyncope and those with syncope in the ED have similar 30‑day serious cardiac outcomes, although patients ...

Patients with noninfectious intermediate, posterior, or panuveitis requiring immunosuppressive therapy are less likely to ...

A smartphone application for muscle relaxation significantly reduces migraine-related disability in patients visiting the ...

General anesthesia leads to better functional outcomes than conscious sedation in stroke patients with large vessel occlusion ...